Company Monitoring Page for Novartis

latest headlines for company on cafepharma

Big gene therapy names line up behind experimental Covid-19 vaccine
Stat
Thu, 05/28/20 - 10:39 am
Tags:
COVID-19, gene therapy, Novartis, AveXis
Novartis builds case for MS drug ofatumumab as FDA decision looms
Pharmaforum
Wed, 05/27/20 - 10:22 am
Tags:
Novartis, ofatumumab, clinical trials, MS, multiple sclerosis
New Zolgensma 'inflection point' is here as Novartis snags EU nod for SMA gene therapy
Fierce Pharma
Wed, 05/20/20 - 10:50 am
Tags:
Novartis, Zolgensma, SMA, spinal muscular atrophy, gene therapy, Europe
Novartis taps Iya Khalil, physicist co-founder of GNS Healthcare, to lead AI Innovation Center
Endpoints
Tue, 05/19/20 - 11:16 pm
Tags:
Novartis, Iya Khalil, GNS Healthcare, artificial intelligence, innovation
With bucks from Pfizer added to their new round, Amplyx steers a tricky course through PhII and a global pandemic
Endpoints
Tue, 05/19/20 - 10:30 am
Tags:
Amplyx, Pfizer, Novartis
Teva bails on price-fixing settlement in gamble on its role fighting COVID-19: report
Fierce Pharma
Mon, 05/18/20 - 10:56 pm
Tags:
Teva Pharmaceutical, price fixing, generics, COVID-19, Sandoz, JNJ, Novartis, Taro Pharmaceuticals
Novartis CEO: COVID-19 vaccine might take until end of 2021 to reach patients
Fierce Pharma
Fri, 05/15/20 - 10:58 am
Tags:
Novartis, Pharma CEOs, vaccines, pandemic, COVID-19, Vas Narasimhan
Novartis-backed Gamida hits goal in phase 3 cancer trial
Fierce Biotech
Tue, 05/12/20 - 12:04 pm
Tags:
Gamida Cell, Novartis, omidubicel, blood cancer, clinical trials
Novartis Drug Wins FDA Approval for Lung Cancers With Specific Mutation
Xconomy
Thu, 05/7/20 - 12:29 am
Tags:
Novartis, Tabectra, FDA, non-small cell lung cancer, capmatinib
Regeneron touts Eylea strength as Novartis rival falters, COVID-19 cuts demand
Fierce Pharma
Tue, 05/5/20 - 01:02 pm
Tags:
Regeneron, Eylea, Novartis, Beovu, COVID-19
The top pharma companies in social media
Fierce Pharma
Mon, 05/4/20 - 11:02 am
Tags:
social media, Boehringer Ingelheim, AbbVie, GSK, Pfizer, Novo Nordisk, Eli Lilly, Novartis
EMA gives thumbs up to key drugs from Novartis, Alexion, Vertex and more
Endpoints
Fri, 05/1/20 - 12:43 pm
Tags:
EMA, Europe, Novartis, Alexion, Vertex Pharmaceuticals
Novartis spinout resTORbio reverse merges with T cell biotech after big PhIII failure
Endpoints
Wed, 04/29/20 - 10:31 am
Tags:
Novartis, ResTORbio, M&A, Parkinson's Disease, Adicet Bio
Novartis to begin trial with canakinumab in COVID-19 pneumonia patients
Pharmaceutical Business Review
Wed, 04/29/20 - 10:21 am
Tags:
Novartis, COVID-19, pneumonia, clinical trials, canakinumab
Roche shares SMA data ahead of scrap with Biogen, Novartis
Fierce Biotech
Tue, 04/28/20 - 10:59 am
Tags:
Roche, Biogen, Novartis, SMA, spinal muscular atrophy, risdiplam, clinical trials
#AACR20: Early data suggest Novartis' Incyte-discovered MET inhibitor helps lung cancer patients with brain lesions
Endpoints
Mon, 04/27/20 - 09:43 am
Tags:
Novartis, Incyte, AACR, lung cancer, MET inhibitors, capmatinib
Novartis, Incyte's Jakafi boosts its case in graft-versus-host disease with another phase 3 win
Fierce Pharma
Wed, 04/22/20 - 10:45 pm
Tags:
Novartis, Incyte, Jakafi, clinical trials, COVID-19, cytokine storm, graft vs host disease
FDA hastens development of Novartis’ Kymriah in follicular lymphoma
Pharmaforum
Wed, 04/22/20 - 10:35 am
Tags:
Novartis, Kymriah, follicular lymphoma, FDA, regenerative medicine
Early treatment with Novartis' Mayzent stalls secondary progressive MS: study
Fierce Pharma
Tue, 04/21/20 - 11:55 pm
Tags:
Novartis, Mayzent, MS, multiple sclerosis, Gilenya
Novartis plans large-scale trial of COVID-19 drug hydroxychloroquine
Pharmaforum
Mon, 04/20/20 - 10:53 am
Tags:
Novartis, hydroxychloroquine, COVID-19, clinical trials

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.